← The patent line

Albuterol Sulfate; Budesonide

Sold as AIRSUPRA · given by inhalation

Three to five years until it comes off patent
3.8 yr
Until anyone may copy it
Protection runs to 2030-05-28
6
Trials running now
947 registered in total
In routine use
Furthest stage reached
already in routine clinical use
3
Organisations running trials
lead sponsors on record
01

Who owns it, and until when

Astrazeneca Pharmaceuticals Lp
Approval holder
the only company permitted to sell it today
2030-05
Last patent expires
latest patent filed against this product
2028-09
FDA exclusivity ends
a separate protection granted at approval

Whichever date falls later is when other manufacturers may apply to sell copies. Price typically falls steeply within a year of that point, and with it any company's ability to recover the cost of new research on the molecule. That is when it becomes a candidate for the ledger on the first tab.

02

What it is being tested for

AsthmaStatus AsthmaticusCOPD
03

Who is paying for the research

Novartis Pharmaceuticals
Company
7
GlaxoSmithKline
Company
4
Boehringer Ingelheim
Company
4

Who funds the trials matters after protection lapses. Company-funded work usually stops once exclusivity ends; university, hospital and government-funded work does not, and is the research most likely to continue on this molecule afterwards.

04

The trials themselves

NCT07342582No trials on record2026 · 670 people · recruiting now
The Rhinovirus Hospitalization and Investiga

Expiry dates are what the patent holder has filed; litigation, paediatric extensions and settlements routinely move them, so read these as the earliest plausible date rather than a schedule. Not medical advice.

← Back to the patent line